Devon J Shedlock

Devon J. Shedlock, Ph.D. is the Chief Scientific Officer of Cell Therapy at Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company.13 Here are some key details about his background and role:

Education and Early Career

Dr. Shedlock received his Ph.D. in cell and molecular biology from the University of Pennsylvania and a B.S. with Honors in biology from Ursinus College.12 Before joining Poseida, he held positions as an adjunct assistant professor of pathology and laboratory medicine at the University of Pennsylvania's Perelman School of Medicine and associate director of the T-Cell Engineering Laboratory in Carl June's group.12

Role at Poseida Therapeutics

• Joined Poseida as its first employee in 201512
• Initially served as Senior Vice President of Research and Development2
• Promoted to Chief Scientific Officer, Cell Therapy in October 20213

Expertise and Contributions

Dr. Shedlock is a key scientific contributor in applying Poseida's proprietary gene engineering platform technologies to develop novel cell therapy programs.1 His areas of expertise include:

• Immunology
• Cell biology
• Molecular biology
• Flow cytometry
• Strategic thinking and business development3

With over 20 years of experience in biotechnology and academics, he has contributed to numerous patents and publications in the field of cell and gene therapy.3 Dr. Shedlock has played a crucial role in advancing multiple product candidates from concept to clinic, including:

• P-PSMA-101: A CAR-T immunotherapy for castrate-resistant prostate cancer
• P-BMCA-101: A CAR-T immunotherapy for multiple myeloma3

Dr. Shedlock's work at Poseida focuses on leveraging the company's genetic engineering platform technologies to create next-generation cell and gene therapeutics with the potential to cure various diseases, including cancer, autoimmune disorders, and infectious diseases.3